MedTrace Logo

Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)

NCT00730431 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2015-04-23

No results posted yet for this study

Summary

The purpose of this study is to obtain single dose safety and pharmacokinetic (PK) data of IDX184 in humans. No formal hypotheses are to be tested in this study.

Conditions

  • Hepatitis C

Interventions

DRUG

IDX184

IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.

DRUG

Placebo

Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-10-31
Completion
2008-10-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00730431 on ClinicalTrials.gov